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The optimal threshold of
high post-treatment platelet
reactivity could be deﬁned by
a point-of-care VerifyNow
P2Y12 assay
We read with great interest the study by Price
et al.,
1 which veriﬁes that high post-treatment
platelet reactivity (HPPR) measured with a
point-of-care VerifyNow assay (Accumetrics
Inc., San Diego, CA, USA) is associated with
post-discharge events after percutaneous
coronary intervention (PCI) with drug-eluting
stent (DES), including stent thrombosis. To
the best of our knowledge, this is the ﬁrst
study to identify a threshold of HPPR of
VerifyNow based on the clinical outcomes.
Recently, a number of studies have demon-
strated that clopidogrel non-responsiveness
proven in the laboratory testing, i.e. HPPR,
has been associated with an increased risk
for cardiovascular events.
2 Light transmittance
aggregometry (LTA) is the gold standard test
to determine the clopidogrel responsiveness.
However, the abundant demands of LTA
make it difﬁcult to utilize in daily practice.
VerifyNow was developed as a point-of-care
test and showed a signiﬁcant correlation
with ADP-induced LTA (r ¼ 0.64 2 0.73).
3
In previous studies using LTA, platelet aggre-
gationof .50%inducedby5 mMADP
4orof
.70% induced by 10 mMA D P
5 has been
suggested an absolute threshold of HPPR for
predicting the ischaemic outcomes. In the
study of Price et al., the optimal cut-off for the
combined endpoint was a post-treatment
reactivity of  235 PRU (P2Y12 reactivity unit)
(area under curve [AUC] 0.711, 95%
conﬁdence interval [CI] 0.529–0.893, P ¼
0.03). Because this study did not show the
association between the HPPRs by a
point-of-care test and ADP-induced LTA, we
estimated the relation using our data. Three
hundred consecutive patients undergoing PCI
with DES implantation at our hospital were
enrolled between October 2007 and March
2008. We performed 5 mM ADP-induced
LTA and VerifyNow using the same blood
sampling via the arterial sheath. LTA was per-
formedinallpatientsaccordingtostandardpro-
tocols.
6 Both PRU (r ¼ 0.641, P , 0.001) and
percentage platelet inhibition (r ¼ 0.679, P ,
0.001) measured by VerifyNow had signiﬁcant
correlations with the results of 5 mM
ADP-induced platelet aggregation. By the
receiver-operating characteristics curve analy-
sis, the optimal cut-off for predicting HPPR on
LTA (5 mM ADP-induced platelet aggregation
.50%) was PRU   239 (AUC 0.794, 95% CI
0.736–0.851, P , 0.001). The PRU value  
239 showed a sensitivity of 83.6% and a speci-
ﬁcityof 68.3%, and was similar to the threshold
of high reactivity value (PRU   235), suggested
by Price et al.
1 The percentage platelet inhi-
bition of  20 was the optimal cut-off for pre-
dicting HPPR on LTA (AUC 0.841, 95% CI
0.790–0.891, P , 0.001), which showed a sen-
sitivity of 76.2% and a speciﬁcity of 83.6%.
A VerifyNow assay has been used widely in
the daily practice instead of LTA. However, its
usefulness for predicting adverse cardiovas-
cular events has been still undetermined.
On the basis of our data analysis, we could
ascertain that high platelet reactivity on
VerifyNow (PRU   235 suggested by Price
et al.) is signiﬁcantly correlated with HPPR
on ADP-induced LTA. It might suggest a sub-
stitutability of VerifyNow in terms of assess-
ment of clopidogrel responsiveness and
practical implication for risk stratiﬁcation.
Funding to pay the Open Access publi-
cation charges for this article was provided
by J.-Y. Hwang, the senior of the Cardiology
Division.
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‘A threshold of platelet
reactivity for ischaemic
events?’ and ‘The optimal
threshold of high post-
treatment platelet reactivity
could be deﬁned by a point-of
care VerifyNow P2Y12 assay’:
reply
We thank Dr Bonello and colleagues and
Jeong and colleagues for their interest in our
paper.
1 We agree with Dr Bonello and col-
leagues that the clopidogrel regimen around
the time of platelet function measurement
is crucial, since this impacts both the level
of platelet reactivity and possibly acute clinical
outcomes. As we note in the methods section
of our paper, patients on chronic clopidogrel
therapy in our study were not re-loaded, and
those who were clopidogrel-naı ¨ve received a
600 mg loading dose. There was no signiﬁcant
difference in ADP-induced platelet reactivity
between these two groups (mean 183 þ 94
PRU vs. 186 þ 73 PRU), nor was there a
difference between these groups in the rate
of patients having high platelet reactivity (28
vs. 35%, P ¼ 0.15).While it does not speciﬁcally
apply to our study, the author’s concern about
the effect of additional clopidogrel loading
doses on platelet function testing around
the time of PCI is a valid one, because the
measured platelet reactivity after an additional
loading dose in patients already on clopido-
grel therapy may not reﬂect steady-state
platelet reactivity on standard maintenance
treatment after discharge. Another issue
raised by Dr Bonello and colleagues is the
interference by glycoprotein IIb/IIIa inhibition
with the particular point-of-care platelet func-
tion assay used in our study. These issues
highlight the challenge of using point-of-care
platelet function testing to stratify long-term
patient risk in the ‘real world’ of clinical prac-
tice where patients receive heterogeneous
clopidogrel therapy and frequent glycoprotein
inhibition around the time of percutaneous
coronary intervention.
Wechosetoreportabsolutepost-treatment
platelet reactivity (HPPR) rather than the per-
centage of receptor inhibition for several
reasons. Baseline reactivity prior to clopidogrel
exposure was not available in all patients, so
that the percentage change in ADP-induced
platelet reactivity after exposure could not be
determined. Although the current VerifyNow
P2Y12 assay that is commercially available
reports a ‘%’ inhibition by comparing the
ratio of ADP-induced reactivity with iso-
TRAP-induced reactivity, this was not available
because the assay device used in a portion of
our study did not contain the iso-TRAP
channel required for this calculation (but did
have the same ADP-channel). However, from
a pathophysiological standpoint, we believe
that post-treatment reactivity is a better
measure of risk. Indeed, the ‘response’ to clopi-
dogrel as measured by percent inhibition may
overestimate the risk of stent thrombosis in
non-responders and underestimate the risk
of stent thrombosis in responders. This is
because patients with low pre-treatment reac-
tivity who demonstrate onlya small percentage
change post-treatment will be categorized
as‘non-responders’despitepersistentlowreac-
tivity. Conversely, patients with very high
pre-treatment reactivity who have a large
percentage inhibition may be categorized as
‘responders’ but continue to have high post-
treatment reactivity.
2
Dr Jeong and colleagues provide important
data regarding the relationship between plate-
let reactivity measured by the VerifyNow
device and light transmittance aggregometry
(LTA). They demonstrate that our ‘optimal’
cut-off for high HPPR with the VerifyNow
P2Y12 assay that we identiﬁed using the
receiver–operator characteristic curve analysis
is consistent with previous, operational deﬁ-
nitions of HPPR proposed by investigators
using LTA. Despite the growing body of data
that support the clinical signiﬁcance of inter-
individual response variability, the clinical impli-
cation of any deﬁnition of HPPR, including
our own, must be veriﬁed in much larger,
prospective studies. Moreover, the appropriate
management of patients with HPPR is
unknown. The Gauging Responsiveness with
A VerifyNow assay- Impact on Thrombosis
And Safety (GRAVITAS) trial (Clinicaltrials.gov
identiﬁer NCT00645918)—a randomized,
placebo-controlled study which is examining
whether an increased clopidogrel maintenance
dose in patients with HPPR reduces throm-
botic events in patients undergoing drug-eluting
stent implantation—may help answer this
question.
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